Bispecific antibody · Immune activation, directed at CD70 and CD3 (CD3E) · developed by Incyte
INCA036873 is a bispecific antibody and T-cell engager that binds CD70 on tumor cells and CD3 on T-cells. By crosslinking cytotoxic T-lymphocytes with CD70-expressing cells, it redirects and activates them to kill the tumor cells. It is studied in solid tumors and hematologic malignancies.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07195916 | Phase 1 | Solid Tumors | Recruiting | INCY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hematologic MalignanciesSolid Tumors
See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INCY catalysts and pipeline →